Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin

FDA Designation: Longboard Pharmaceuticals has received orphan drug designation from the U.S. FDA for bexicaserin, aimed at treating Lennox-Gastaut Syndrome.

Implications of Designation: This designation may facilitate the development and commercialization of bexicaserin for patients suffering from this rare form of epilepsy.